9
Views
16
CrossRef citations to date
0
Altmetric
Original Article

Monthly Update: Central & Peripheral Nervous Systems: Pharmacology of antimigraine 5-HT1D receptor agonists

&
Pages 581-593 | Published online: 03 Mar 2008
 

Abstract

The 5-HT 1D receptor agonist sumatriptan is undoubtedly a significant advance in the management of migraine and cluster attacks. Notwithstanding, sumatriptan has some important shortcomings, which include low oral bioavailability, headache recurrence (possibly due to short t1/2) and contraindication in patients with coronary artery disease. These shortcomings, as well as lofty sales potentials, have stimulated the search and design of second-generation 5-HT1D receptor agonists. The large list of such compounds is growing, but those that are likely to be marketed in this millennium include: zolmitriptan, MK-462, naratriptan, BMS-180048 and, perhaps, the non-indole derivative alniditan. However, none of the newer 5-HT1D receptor agonists, as is also the case with sumatriptan, shows selectivity towards either the 5-HT1Dα or the 5-HT1Dβ receptor subtype and there seems to be little qualitative difference in their pharmacological profiles. Thus, these compounds suppress adenylyl cyclase activity, contract isolated cerebral (e.g., human, bovine or canine middle cerebral artery) as well as, though weakly, some peripheral arteries (e.g., human coronaries), reduce carotid artery blood flow in the cat, dog or pig by a selective action on arteriovenous anastomoses, and inhibit dural plasma extravasation (rat) and evoked potentials in dorsal horn neurones (cat) following trigeminal ganglion stimulation. Human brachial arteriovenous anastomoses are also constricted by sumatriptan. The newer 5-HT1D receptor agonists appear to offer some advantage over sumatriptan with respect to bioavailability, onset of action or headache recurrence.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.